(Q59616913)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Michael A Fridrik

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

R Jakesz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

H Samonigg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

E Kubista

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

P Steindorfer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

H Hausmaninger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

P Sevelda

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

B Tschurtschenthaler

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

M Stierer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

R Kolb

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

G Steger

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

12 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

66-70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients: 10 year results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. II. Patients without involved axillary lymph nodes.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Postmenopausal breast cancer: is the short-term pain worth the long-term gain?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Factors affecting treatment decisions for a life-threatening illness: the case of medical treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Dose-response effect of adjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Cyclin D1 and prognosis in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

How does the message of cancer specialists affect routine medical practice? Only sixty percent of surgical adjuvant breast cancer treatment is based on hormone receptor status

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910010-7

7 January 2021

10.1016/S0959-8049(97)10010-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624239%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference